0000899243-20-001815.txt : 20200123
0000899243-20-001815.hdr.sgml : 20200123
20200123160523
ACCESSION NUMBER: 0000899243-20-001815
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200121
FILED AS OF DATE: 20200123
DATE AS OF CHANGE: 20200123
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: LOVE TED W
CENTRAL INDEX KEY: 0001188919
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37539
FILM NUMBER: 20542116
MAIL ADDRESS:
STREET 1: C/O GLOBAL BLOOD THERAPEUTICS, INC.
STREET 2: 400 EAST JAMIE COURT, SUITE 101
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Global Blood Therapeutics, Inc.
CENTRAL INDEX KEY: 0001629137
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 274825712
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 171 OYSTER POINT BLVD, SUITE 300
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
BUSINESS PHONE: 650741-7700
MAIL ADDRESS:
STREET 1: 171 OYSTER POINT BLVD, SUITE 300
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2020-01-21
0
0001629137
Global Blood Therapeutics, Inc.
GBT
0001188919
LOVE TED W
C/O GLOBAL BLOOD THERAPEUTICS, INC.
171 OYSTER POINT BLVD., SUITE 300
SOUTH SAN FRANCISCO
CA
94080
1
1
0
0
See Remarks
Common Stock
2020-01-21
4
S
0
29311
81.9773
D
1112673
D
Common Stock
2020-01-21
4
S
0
10166
82.782
D
1102507
D
Common Stock
2020-01-21
4
S
0
523
83.5615
D
1101984
D
Common Stock
2020-01-22
4
S
0
6819
81.0142
D
1095165
D
Common Stock
2020-01-22
4
S
0
32150
81.8538
D
1063015
D
Common Stock
2020-01-22
4
S
0
1031
82.4549
D
1061984
D
Common Stock
2500
I
By Daughter
Common Stock
2500
I
By Daughter
This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person.
Represents the weighted average sale price of the shares sold ranging from $81.31 to $82.30 per share, inclusive. The Reporting Person will provide, upon request by the Issuer, a security holder of the Issuer, or the staff of the Securities and Exchange Commission, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Represents the weighted average sale price of the shares sold ranging from $82.32 to $83.18 per share, inclusive. The Reporting Person will provide, upon request by the Issuer, a security holder of the Issuer, or the staff of the Securities and Exchange Commission, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Represents the weighted average sale price of the shares sold ranging from $83.355 to $83.73 per share, inclusive. The Reporting Person will provide, upon request by the Issuer, a security holder of the Issuer, or the staff of the Securities and Exchange Commission, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Represents the weighted average sale price of the shares sold ranging from $80.35 to $81.34 per share, inclusive. The Reporting Person will provide, upon request by the Issuer, a security holder of the Issuer, or the staff of the Securities and Exchange Commission, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Represents the weighted average sale price of the shares sold ranging from $81.35 to $82.345 per share, inclusive. The Reporting Person will provide, upon request by the Issuer, a security holder of the Issuer, or the staff of the Securities and Exchange Commission, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Represents the weighted average sale price of the shares sold ranging from $82.355 to $82.60 per share, inclusive. The Reporting Person will provide, upon request by the Issuer, a security holder of the Issuer, or the staff of the Securities and Exchange Commission, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
President and Chief Executive Officer
/s/ Lesley Ann Calhoun, as Attorney-in-Fact
2020-01-23